In the context of ovarian cancer, such analyses can reveal how simultaneous modulation of FOXP3 and EGFR signaling may influence immune checkpoint regulators, including PD-1/PD-L1 and CTLA-4, which are crucial in tumor immune evasion. Here, FOXP3 is linked to neoplasm.